12-month outcomes of photobiomodulation in dry age-related macular degeneration: a prospective multicentre randomised double-masked controlled clinical trial

Macular Diseases

Clinical efficacy and safety of aflibercept biosimilars in neovascular age-related macular degeneration: a systematic review and meta-analysis of randomised controlled trials

Br J Ophthalmol

Zhang C, Sonik NR, Ayoubi M, AbouKasm G, Zhu D, Fan JC, Albini TA, Yannuzzi NA

doi: 10.1136/bjo-2025-328196

Macular Diseases

One-year clinical outcomes of four-dose induction versus immediate treat-and-extend faricimab regimens in pretreated neovascular age-related macular degeneration

BMC Ophthalmol

Menghini M, Grimaldi G, Paris A, Bachmann LM, Schmid MK

doi: 10.1186/s12886-025-04463-4

Macular Diseases

Diverse-Ancestry GWAS of Age-Related Macular Degeneration on 16,108 Examined Cases and 18,038 Controls

Invest Ophthalmol Vis Sci

Gorski M, Grunin M, Herold JM, Fröhlich B, Behr M, Wheeler N, Bush WS, Song YE, Zhu X, Blanton SH, Pericak-Vance MA, Heid IM, Haines JL, International Age-Related Macular Degeneration Genomics Consortium

doi: 10.1167/iovs.66.13.51

Macular Diseases

Adherence to intravitreal aflibercept in neovascular age-related macular degeneration: 24-month results from the ANDROMEDA study

Ophthalmol Retina

Holz FG, Ziemssen F, Bauer Steinhusen U, Wachtlin J, Schürks M, Lorenz K, Scholz P, Machewitz T, Rech C, Lanzl I, Lommatzsch A, Finger RP, ANDROMEDA Study Group

doi: 10.1016/j.oret.2025.09.004

Macular Diseases

Age-related choroidal atrophy: A systematic review of multimodal imaging, clinical features, and differentiation from other forms of macular degeneration

Surv Ophthalmol

Lai A, Issa M, Pereira A, Ghafri MA, Dollin M, Hurley B, Chhablani J, Yan P

doi: 10.1016/j.survophthal.2025.12.005

Retinal Diseases

Intravenous alteplase versus oral aspirin for acute central retinal artery occlusion within 4·5 h of severe vision loss (THEIA): a multicentre, double-dummy, patient-blinded and assessor-blinded, randomised, controlled, phase 3 trial

Lancet Neurol

Préterre C, Gaultier A, Obadia M, Vignal C, Mourand I, Plat J, Sablot D, Gaudron M, Rodier G, Godeneche G, Urbanczyk C, Marc G, Massardier E, Adam S, Boulanger M, Marcel S, Mechtouff L, Ronzière T, Calvière L, Godard-Ducceschi S, Barbin L, Lebranchu P, Guillon B, THEIA collaborators

doi: 10.1016/S1474-4422(25)00308-4

Macular DiseasesRetinal Diseases

Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 2-year efficacy and safety results from the GATHER2 phase 3 trial

Ophthalmology

Khanani AM, Danzig CJ, Heier JS, Jaffe GJ, Kaiser PK, Lally DR, Patel SS, Vajzovic L, Weng CY, Patel H, Clark J, Desai D, Luo D, Henry E, Holz FG, GATHER2 trial investigators

doi: 10.1016/j.ophtha.2025.12.011

Macular Diseases

Nonexudative Macular Neovascularization in Age-Related Macular Degeneration

JAMA Ophthalmol

Thottarath S, Gurudas S, Kubravi S, Kazantzis D, Keskin AM, Sivaprasad S, EYENEON Study Group

doi: 10.1001/jamaophthalmol.2026.0459

Macular Diseases

One-Year Real-World Outcomes of Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

Ophthalmol Ther

Grimaldi G, Bartolomeo N, Garweg JG, Pfister IB, Schild C, Peyla A, Tillmann A, De Oliveira Figueiredo EC, Spitznagel T, Kitay AM, Gabathuler F, Zweifel S, Kurz-Levin MM, Ebneter A, Somfai GM, Eandi CM, Munk MR, Ambresin A, Menghini M

doi: 10.1007/s40123-025-01305-w

Related content

Clinical efficacy and safety of aflibercept biosimilars in neovascular age-related macular degeneration: a systematic review and meta-analysis of randomised controlled trials

One-year clinical outcomes of four-dose induction versus immediate treat-and-extend faricimab regimens in pretreated neovascular age-related macular degeneration

Diverse-Ancestry GWAS of Age-Related Macular Degeneration on 16,108 Examined Cases and 18,038 Controls

Adherence to intravitreal aflibercept in neovascular age-related macular degeneration: 24-month results from the ANDROMEDA study

Age-related choroidal atrophy: A systematic review of multimodal imaging, clinical features, and differentiation from other forms of macular degeneration

Intravenous alteplase versus oral aspirin for acute central retinal artery occlusion within 4·5 h of severe vision loss (THEIA): a multicentre, double-dummy, patient-blinded and assessor-blinded, randomised, controlled, phase 3 trial

Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 2-year efficacy and safety results from the GATHER2 phase 3 trial

Nonexudative Macular Neovascularization in Age-Related Macular Degeneration

One-Year Real-World Outcomes of Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report